The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study (TaxXel) on the treatment with docetaxel in combination with capecitabin in patients with metastatic esophageal cancer or cancer in the cardia region.
Signe Friesland
No relevant relationships to disclose
Gun Wickart-Johansson
No relevant relationships to disclose
Lianna Kadar
No relevant relationships to disclose
Charlotte Bratthall
No relevant relationships to disclose
Henry Letocha
No relevant relationships to disclose
Lars Franzen
No relevant relationships to disclose
Anne-Birgitte Jacobsen
No relevant relationships to disclose
Petra Weber Hauge
No relevant relationships to disclose
Gunnar Wagenius
No relevant relationships to disclose
Ingunn Hatlevoll
No relevant relationships to disclose
Nils Glenjen
No relevant relationships to disclose